CheckMate 915
CheckMate 915 asked whether adding a low dose of ipilimumab to nivolumab after melanoma surgery would prevent more recurrences; it did not, and added toxicity, so single-agent PD-1 blockade remains the adjuvant standard.
Overview
Nivolumab plus ipilimumab is the most active combination in advanced melanoma, and CheckMate 915 tested whether a lower-toxicity version (ipilimumab 1 mg/kg every six weeks) would improve on nivolumab alone after complete resection of stage IIIB to IV melanoma. It randomised 1844 patients, with recurrence-free survival in the whole population and in PD-L1-low tumours as the dual primary endpoints.
The combination did not improve recurrence-free survival in either population and caused more treatment-related adverse events. Adjuvant nivolumab or pembrolizumab alone remain the standards, and later trials have tested relatlimab (RELATIVITY-098) and neoadjuvant approaches (NADINA) instead.
Similar pages
not linked directly; found by shared links- TrialCheckMate 227
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialCheckMate 358
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialATTRACTION-2
Shares Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialCheckMate 025
Shares Bristol Myers Squibb, Nivolumab and the tag subtype-trials.
- TrialMEDALIST
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialDASISION
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialAZA-001
Shares Bristol Myers Squibb and the tag subtype-trials.
- TrialCOMMANDS
Shares Bristol Myers Squibb and the tag subtype-trials.